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Abstract
Rationale: Peripheral blood biomarkers are needed to identify and determine the extent of idiopathic pulmonary fibrosis
(IPF). Current physiologic and radiographic prognostic indicators diagnose IPF too late in the course of disease. We
hypothesize that peripheral blood biomarkers will identify disease in its early stages, and facilitate monitoring for disease
progression.
Methods: Gene expression profiles of peripheral blood RNA from 130 IPF patients were collected on Agilent microarrays.
Significance analysis of microarrays (SAM) with a false discovery rate (FDR) of 1% was utilized to identify genes that were
differentially-expressed in samples categorized based on percent predicted DLCO and FVC.
Main Measurements and Results: At 1% FDR, 1428 genes were differentially-expressed in mild IPF (DLCO .65%) compared
to controls and 2790 transcripts were differentially- expressed in severe IPF (DLCO .35%) compared to controls. When
categorized by percent predicted DLCO, SAM demonstrated 13 differentially-expressed transcripts between mild and severe
IPF (, 5% FDR). These include CAMP, CEACAM6, CTSG, DEFA3 and A4, OLFM4, HLTF, PACSIN1, GABBR1, IGHM, and 3
unknown genes. Principal component analysis (PCA) was performed to determine outliers based on severity of disease, and
demonstrated 1 mild case to be clinically misclassified as a severe case of IPF. No differentially-expressed transcripts were
identified between mild and severe IPF when categorized by percent predicted FVC.
Conclusions: These results demonstrate that the peripheral blood transcriptome has the potential to distinguish normal
individuals from patients with IPF, as well as extent of disease when samples were classified by percent predicted DLCO, but
not FVC.
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Introduction
Idiopathic Pulmonary Fibrosis (IPF) is categorized as an
interstitial lung disease (ILD) and is the most common subtype
of idiopathic interstitial pneumonias (IIP) comprising nearly 71%
of the total cases [1]. Of the IIPs, IPF has the poorest prognosis
with a 50% mortality rate 3 years following diagnosis [2].
Prognostic indicators of IPF include progressive deterioration of
clinical symptoms such as dyspnea, pulmonary function, and
extent of disease on high-resolution chest CT [3–7]. While
dyspnea scores have been used as a predictor of survival in IPF
patients [8], it remains an ambiguous prognostic indicator since it
is highly subjective. Pulmonary function tests such as diffusing
capacity for carbon monoxide (DLCO) and forced vital capacity
(FVC) have been utilized as predictive indicators [9,10]. Studies
demonstrate that a DLCO of ,35% or a decline in DLCO .15%
within a year period are associated with an increased mortality.
Similarly, a decline of .10% in FVC over a six month period also
indicated an earlier mortality [8,11]. The overall extent of fibrosis
on high-resolution chest CT (HRCT) characterized by a
honeycomb pattern and reticulation predict survival [12].
Randomized prospective controlled clinical trials in IPF have
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e37708demonstrated significant differences in the rate of decline in FVC
and DLCO among the placebo arms of the trials indicating there is
substantial disease heterogeneity within IPF [13]. Current
indicators of disease progression fail to capture the dynamic
biology associated with IPF particularly patients at risk for acute
exacerbations of IPF [14]. Biomarkers that measure disease stage
and activity would be of benefit in understanding the effects of
novel treatments, disease progression, and the design of clinical
trials with homogenous placebo and treatment groups.
Rosas and coworkers observed a differential expression of
MMP7, MMP1, MMP8, IGFBP1, and TNFRSF1A proteins in
the peripheral blood between familial interstitial pulmonary
fibrosis and controls [15]. However, the use of these biomarkers
to differentiate disease severity or extent of disease within the IPF
cohort was not addressed. We hypothesize that peripheral blood
transcriptional profiles from patients with IPF would enable us to
distinguish patients with IPF from controls, and mild from more
advanced disease stage, and allow for monitoring of the
progression of disease in either sporadic or familial IPF.
Methods
Study Populations
One hundred thirty peripheral blood RNA specimens were
collected from individuals enrolled in either the Interstitial Lung
Disease (ILD) or the Familial Pulmonary Fibrosis (FPF) Programs
conducted at National Jewish Health and Duke University. Only
one individual case per family was utilized from the FPF
repository. Individual samples had a consensus diagnosis of
probable or definite IPF, and this was based on the ATS/ERS/
JRS/ALAT criteria [16]. Subjects were excluded from selection if
they were current smokers, or currently treated with agents that
could alter mRNA levels such as glucocorticoids, azathioprine, or
other immunomodulators. One-hundred twenty three RNA
samples passed quality assurance parameters after RNA extrac-
tion, probe synthesis, and hybridization for further analysis. 53 of
these samples were from sporadic cases of IPF, and 70 samples
were from familial IPF. Peripheral blood gene expression profiles
were analyzed on groups of individuals based on disease severity.
Two pulmonary function measurements, DLCO and FVC, were
used to stratify the cases into severe and mild disease categories.
Mild disease is defined as either percent predicted DLCO $65%
(N=16) or FVC $75% (N=27). Severe disease is defined as
either DLCO #35% (N=15), FVC #50% (N=13). All of these
were also compared to age and gender matched non-diseased,
healthy controls (N=27). Eight patients categorized as severe were
used in both the DLCO and FVC analysis, whereas the mild
disease classified by either DLCO or FVC are all distinct cases.
Healthy control subjects are family members who participated in
screening for the presence of pulmonary fibrosis, and after
evaluation of their medical history, lung function, and chest CT,
they were found to have no evidence of lung disease. Individual
institutional review boards approved this research. All participants
in this study provided written IRB-approved informed consent.
Pulmonary Function Testing
FEV1 and DLCO measurement were obtained according to
American Thoracic Society standards and guidelines [17].
Expression Profiling
Peripheral blood RNA isolation and
purification. Peripheral blood samples were collected in
PAXgene RNA tubes (PreAnalytiX, 762165). RNA extraction
and purification was performed manually utilizing the PAXgene
Blood RNA kit (PreAnalytiX, 762164) according to the manufac-
turer’s protocol.
Total RNA quantification and quality
characterization. Quantification of total RNA was measured
via the Nanodrop ND-1000 spectrophotometer (NanoDrop
Technologies, Wilmington, DE). Quality of the RNA was assessed
with a RNA 6000 NanoChip (Agilent, Palo Alto, CA) on the 2100
Bioanalyzer (Agilent, Palo Alto, CA) by ratio comparison of the
18 S and 28 S rRNA bands.
Microarrays. Agilent Whole Human Genome Oligonucleo-
tide Microarrays (Agilent, Palo Alto, CA), were used to determine
gene expression levels in peripheral blood. Total RNA was used as
a template for synthesis of cDNA utilizing the One Color Low
Input Agilent Quick Amp Labeling Kit utilizing the Spike-In Kit
to provide positive controls. The Agilent one-color microarray
based gene expression analysis was followed per manufacturer’s
instructions, and passed Agilent’s quality control (QC).
Microarray data analysis. Analysis was performed utilizing
the Multi-Experiment Viewer (MeV) software package [18].
Significance analysis of microarrays (SAM) with a false discovery
rate (FDR) of 1% and 5%, assessed by performing 100
permutations, was performed within the program to identify genes
that were differentially-expressed between IPF samples categorized
by percent predicted DLCO and FVC. All IPF samples were
compared to normal controls to identify differentially-expressed
genes. Principal component analysis (PCA) was carried out on
genes identified by SAM analyses to identify outliers, and gene-
based hierarchical clustering was performed to identify relation-
ships among differentially-expressed genes related to mild or
severe disease categorized by DLCO. All microarray data is
minimal information about a microarray experiment (MIAME)
compliant, and raw data has been deposited into the GEO
database (GSE33566).
Gene ontology and functional network analysis. Data
were analyzed through the use of Ingenuity Pathways Analysis
(Ingenuity Systems, www.ingenuity.com). The Canonical Path-
ways Analysis identified the pathways, and the significance of these
was determined by Fischer’s exact test. Biomarker Analysis was
employed to identify the most relevant molecular biomarker
candidates.
Validation. Quantitative real-time PCR was utilized to
confirm differential expression of genes discovered by microarray
analysis with an ABI 7900 HT Fast Real-Time PCR Detection
System (Applied Biosystems, Foster City, CA) using forty cycles of
amplification. All assays were performed in duplicate and data
were analyzed by the DDCt method utilizing glyceraldehyde 3
phosphate dehydrogenase (GAPDH) as an endogenous control
[19].
Results
Demographics and Disease Severity
Age, gender, and smoking history of the study population
stratified into mild and severe disease groups based on pulmonary
function status (Tables 1 and 2) show a mean FVC of 85%
predicted and DLCO 77.1% predicted in the mild disease group,
and a mean FVC 42.5% predicted and 27.5% predicted DLCO in
the severe disease group. The mean age is similar between groups
when classified by either % predicted FVC (P=0.18), or %
predicted DLCO (P=0.87), but the mean age of either disease
group is slightly older compared to controls (P=0.15). The
majority of patients are male in both mild and severe disease
categories, and similar between both disease categories when
classified by either % predicted FVC (P=0.48) or % predicted
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mild and severe disease categories with respect to prior tobacco
use. The diagnosis of IPF was confirmed by surgical lung biopsy in
50.7% of the study subjects (seeTables S1, S2, S3, and S4). A
highly confident diagnosis of definite IPF was obtained in 90% of
patients (64 of 71, Table S1, S2, S3, and S4). Five patients with
mild disease by DLCO ($ 65% predicted) failed to meet definite
HRCT criteria for IPF due to minimal honeycombing, and are
categorized as probable IPF since the predominate HRCT
findings are sub-pleural, bilateral, bi-basilar reticulation, and
traction bronchiectasis, and clinical features supported the
diagnosis of IPF. Of these 5 cases, the mean age is 70 (range
63–75), 4 of the 5 cases are male, and is consistent with IPF.
Identification of a Peripheral Blood Signature that
Distinguishes Presence of Disease
Principal component analysis (PCA) was performed to deter-
mine outliers in the gene expression data based on disease
categorization (mild or severe IPF vs. normal). The majority of
mild cases (DLCO $65% predicted), both probable and definite,
cluster along the first principal component (Figure 1). Two cases of
probable IPF distribute with controls, and one control distributes
with cases along the first principal component. Both of the
probable cases that distributed with controls have very early
disease, and they had mild disease on HRCT. The first case had a
normal DLCO of 99% predicted, only a mildly reduced FVC of
71% predicted, and the second case case had a DLCO of 66% and
FVC of 86% predicted. Severe cases of IPF (DLCO #35%), both
probable and definite, distribute together along the first principal
component (Figure 2). Three cases of advanced pulmonary fibrosis
that by pathology review were deemed unclassifiable fibrotic lung
disease due to advanced honeycomb lung but most consistent with
IPFwere included in the analysis (Tables S1, S2, S3), and are
similar to other cases of severe definite IPF. This demonstrates the
potential of the peripheral blood molecular signature to diagnose
patients when the interpretation of surgical lung biopsy is
ambiguous. One control distributes with cases and is misclassified
by PCA, and one control is not readily classified based on the first
and second principal components. Thus, it is unlikely that the
peripheral blood signature will achieve 100% accuracy to predict
the presence of IPF.
Significant analysis of microarray (SAM) of the mild IPF cohort,
whencategorizedbypercentpredictedDLCO(N=16)comparedto
normal controls (N=31) revealed 1,428 differentially-expressed
transcripts (Table S6), and when categorized as severe IPF (N=15)
compared to normal controls (N=31), 2,790 differentially-
expressed transcripts (table S7) with ,1% false discovery rate
(FDR). Tables 3 and 4 list the differentially-expressed genes with at
least a log2 2 fold change in expression (While a few genes are in
common, there are different sets of genes have at least a log2 2-fold





Identification of a Peripheral Blood Signature that
Distinguishes Extent of Disease
Principal component analysis was performed to determine
outliers in the data set based on severity of disease categorization.
Results demonstrate that 1 severe IPF case appears to be clinically
misclassified as a mild case of IPF, while other cases are correctly
classified as mild or severe (Figure 3). Significance analysis of
microarrays (SAM) of IPF samples, when categorized by percent
predicted DLCO (DLCO $65% [N=16] and DLCO #35%
[N=15]), demonstrated 13 differentially-expressed transcripts
with less than a 5% false discovery rate. Table 5 lists all
differentially-expressed genes found between mild and severe
cases of IPF categorized by DLCO. When using a FDR of #1%,
only defensin A3 (DEFA3) is differentially-expressed between both
mild or severe cases compared to controls. SAM revealed no
differentially-expressed transcripts with less than a 5% false
discovery rate between peripheral blood samples when IPF
patients were categorized by percent predicted FVC (N=27 and
N=13, data not shown).
Peripheral Blood Signature Disease Progression Analysis
The general comparison analysis tool of the Ingenuity Pathway
Analysis (IPA) software was utilized to identify the intersection or
common differentially-expressed transcripts between normal and
mild IPF, normal and severe IPF, and mild versus severe IPF
when classified by DLCO for the purpose of discovery common
potential biomarkers. This analysis showed that at FDR ,5%
only 2 differentially expressed transcripts, A3 (DEFA3) and
hypothetical protein FLJ11710 , were differentially-expressed
between control vs mild, mild vs severe, and control vs severe
disease (DLCO #35%). There is up-regulation in DEFA3
expression compared to controls for severe IPF, while hypothet-
ical protein FLJ11710 demonstrates a down regulation compared
to controls for severe IPF. Between the mild and severe IPF
cohort , and between normal and severe disease, there is up-
regulation of several other host defense genes including defensin
Table 1. Clinical and demographic IPF variables categorized by FVC.
Variable Characteristics Mild IPF (N=27) Severe IPF (N=13) Controls (N=27)
% Predicted FVC 85.068.1 42.566.6 NR
Age Mean6SD 69.868.4 65.3612.7 60.1614.1
Sex Male/Female 19/8 10/3 11/17
Smoking Status Current 0 0 0
Former 7 7 14
Never 18 6 13
Not Reported 2 0 0
Abbreviations: Idiopathic Pulmonary Fibrosis (IPF); Not Reported (NR); Diffusing Capacity for Carbon Monoxide (DLCO); Forced Vital Capacity (FVC).
doi:10.1371/journal.pone.0037708.t001
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spin G (CTSG), and down-regulation of immunoglobulin heavy
chain constant mu (IGHM). The greatest increase found
distinguishing controls from severe disease, and mild from severe
disease is olfactinmedin 4 (OLFM4). We randomly selected 4 of
the 13 differentially-expressed genes for qPCR validation, and
qPCR confirmed the differential expression of these genes
identified by microarray experiments (Table S8).
We also subjected the list of 13 differentially expressed genes
based on DLCO (5%FDR, Table 5) to a functional analysis
utilizing the Ingenuity Pathway Analysis (IPA) software. The
functional analysis tool also calculates a significance value that is
a measure for the likelihood that the association between a set
of genes and a given process is due to random chance. Ten of
the 13 differentially-expressed genes had annotations represent-
ing a gene, protein or chemical that was able to be mapped to
an associated network. The associated network functions (Table
S5) included: 1) inflammatory response (P,0.05), 2) cellular
movement (P,0.05), 3) immune trafficking, 4) genetic disorder
(P,0.05); and 4) cell-to-cell signaling (P,0.05). Figure 4 shows
an overlay of all three associated networks illustrating both
direct and indirect relationship pathways of the differentially-
expressed genes. Finally, given that more than one a-defensin
and other host defense-related proteins that distinguish normal,
mild, and severe disease, we analyzed pathway interactions with
a-defensins (Figure 5), and note an interaction with metallopro-
teinase 7 (MMP7) which activates a-defensins by proteolytic
cleavage.
Table 2. Clinical and demographic IPF variables categorized by DLCO.
Variable Characteristics Mild IPF (N=16) Severe IPF (N=15) Controls (N=27)
% Predicted DLCO 77.1611.9 27.465.3 NR
Age Mean6SD 67.466.0 66.8613.7 60.1614.1
Sex Male/Female 11/5 11/4 11/17
Smoking Status Current 0 0 0
Former 7 10 14
Never 8 5 13
Not Reported 1 0 0
Abbreviations: Idiopathic Pulmonary Fibrosis (IPF); Not Reported (NR); Diffusing Capacity for Carbon Monoxide (DLCO); Forced Vital Capacity (FVC).
doi:10.1371/journal.pone.0037708.t002
Figure 1. Principal component analysis of mild IPF cases (DLCO $65% predicted) compared to controls. Dark blue spheres: definite IPF;
Cyan/light blue spheres: probable IPF; Green spheres: healthy controls. Axis labels: white-first principal component; blue-second principal
component; lavender- third principal component. The majority of cases, both probable and definite, cluster along the first principal component. Two
cases of probable IPF distribute with controls, and one control distributes with cases along the first principal component.
doi:10.1371/journal.pone.0037708.g001
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This is the first study to investigate the IPF peripheral blood
transcriptome based on disease severity defined by lung functional
parameters. Our findings provide evidence that the peripheral
blood transcriptome can be used to develop signatures that identify
the presence and disease extent of IPF. We demonstrate a
composite signature that distinguishes normal controls from IPF,
13 genes that distinguish mild from severe IPF utilizing DLCO
values. Importantly, when a stringent false discovery rate of #1%
is used, the genes that demonstrate the greatest differential-
expression between control and mild disease, and control and
severe disease are different. These data indicate that molecular
signatures from the peripheral blood transcriptome that are
intended to predict the presence of IPF will need to be take into
account disease severity. There was differential-expressionof
several inflammatory response and immune trafficking genes
including a-defensins that are proteolytic substrates of MMP7.
MMP7 has previously been shown to be over-expressed in IPF
lung and serum, and its increased expression is associated with
decreased survival [20]. These findings suggest that decreases in
DLCO in IPF may be related to immune trafficking genes such as
a-defensins.
We have identified that the peripheral blood transcriptome has
the potential to discriminate controls from mild or severe IPF, and
distinguish mild from severe disease using a cohort of both
sporadic and familial IPF. Our previous gene expression studies
indicate sporadic and familial IPF have similar gene expression
patterns in lung [21]. Additionally, we have previously identified a
promoter polymorphism in MUC5B that increase the risk of
developing either sporadic or familial IPF [22]. Consequently, we
believe both sporadic and familial IPF can be considered to be
more similar than different, and justifies combining these in the
current analysis.
Recent studies using plasma or serum protein markers have
identified several proteins that might indicate disease presence or
survival. Reduced survival has been associated with elevated
Figure 2. Principal component analysis of severe IPF (DLCO
#35% predicted). Red spheres: definite IPF; Orange spheres:
probable IPF; Yellow spheres: unclassifiable fibrosis; Green spheres:
healthy controls. Axis labels: white-first principal component; blue-
second principal component; lavender- third principal component. The
majority of severe cases, both probable and definite, cluster along the
first principal component. Three cases of unclassifiable fibrosis
distribute with IPF cases.
doi:10.1371/journal.pone.0037708.g002
Table 3. Differentially-expressed genes that distinguish mild IPF from control.
Gene Symbol Description Fold Change{
CEACAM4 carcinoembryonic antigen-related cell adhesion molecule 4 4.02
IL1R2 interleukin 1 receptor, type II 2.69
FCN1 ficolin (collagen/fibrinogen domain containing) 1 2.36
GRN granulin 2.33
PTGIR prostaglandin I2 (prostacyclin) receptor (IP) 2.30
HLA-B major histocompatibility complex, class I, B 2.27
DYSF dysferlin, limb girdle muscular dystrophy 2 2.25
LILRB3 leukocyte immunoglobulin-like receptor, subfamily B (3) 2.21
TALDO1 transaldolase 1 2.21
CXCR2 chemokine (C-X-C motif) receptor 2 2.19
FKBP5 FK506 binding protein 5 2.17
SORL1 sortilin-related receptor, L(DLR class) A repeats-containing 2.16
IMPDH1 IMP (inosine monophosphate) dehydrogenase 1 2.15
DAPK2 death-associated protein kinase 2 2.14
CA4 carbonic anhydrase IV 2.13
MMP9 matrix metallopeptidase 9 (gelatinase B) 2.11
PSAP prosaposin 2.09
TUBA3D tubulin, alpha 3d 22.08
RPL24 ribosomal protein L24 22.17
GPR78 G protein-coupled receptor 78 22.68
{Significance analysis of microarrays (SAM) of IPF samples when categorized by percent predicted DLCO $65% [N=16]. Differentially- expressed transcripts with ,1%
false discovery rate and . 2-fold change in expression are represented. Fold changes are expressed as log2 ratio. See supplementary tables for a complete list of
differentially-expressed genes and corresponding accession numbers.
doi:10.1371/journal.pone.0037708.t003
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Gene Symbol Description Fold Change
IL1R2 interleukin 1 receptor, type II 3.43
DEFA3 defensing, alpha 3, neutrophil specific 3.39
OLFM4 olfactomedin 4 3.39
MMP9 matrix metallopeptidase 9 (gelatinase B) 3.32
GRB10 growth factor receptor-bound protein 10 3.25
DEFA4 defensin, alpha 4, corticostatin 3.00
LTF lactotransferrin 2.97
RAB8A RAB8A, member RAS oncogene family 2.76
CTSG cathepsin G 2.64
CAMP cathelicidin antimicrobial peptide 2.64
CEACAMP8 carcinoembryonic antigen-related cell adhesion (8) 2.53
VSIG4 V-set and immunoglobulin domain containing 4 2.50
PGLYRP1 peptidoglycan recognition protein 1 2.45
FKBP5 FK506 binding protein 5 2.45
LOC151438 hypothetical protein LOC151438 2.43
ECHDC3 enoyl Coenzyme A hydratase domain containing 3 2.34
LOC100130890 similar to hCG2030844 22.34
PRSS36 protease, serine, 36 22.37
MCAT malonyl CoA:ACP acyltransferase (mitochondrial) 22.42
IGHM immunoglobulin heavy constant mu 23.0
{Significance analysis of microarrays (SAM) of IPF samples when categorized by percent predicted DLCO #35% [N=15]. Differentially- expressed transcripts with ,1%
false discovery rate and $ 2-fold change in expression are represented. Fold changes are expressed as log2 ratio. See supplementary tables for a complete list of
differentially-expressed genes and corresponding accession numbers.
doi:10.1371/journal.pone.0037708.t004
Figure 3. Principal component analysis of IPF samples grouped by extent of disease correlated with DLCO % predicted (mild $65%,
severe #35%). Red spheres: definite IPF; Orange spheres: probable IPF; Yellow spheres: unclassifiable fibrosis;Blue spheres: mild IPF; Green spheres:
severe cases of IPF. Axis labels: white-first principal component; blue-second principal component; lavender- third principal component.
doi:10.1371/journal.pone.0037708.g003
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Symbol Entrez Gene Name Probe ID Accession Number Fold Change Location





A_23_P421483 BC005008 2.353 Plasma Membrane
CTSG cathepsin G A_23_P140384 NM_001911 2.703 Cytoplasm
DEFA3 (includes
EG:1668)
defensin, alpha3, neutrophil-specific A_23_P31816 NM_005217 2.379 Extracellular Space
DEFA4 (includes
EG:1669)
defensin, alpha 4, corticostatin A_23_P326080 NM_001925 3.713 Extracellular Space
OLFM4 olfactomedin 4 A_24_P181254 NM_006418 3.807 unknown
HLTF helicase-like transcription factor A32_P210798 BF513730 1.413 unknown
PACSIN1 protein kinase C and casein kinase
substrate in neurons 1
A_23_P258088 NM_020804 21.511 Cytoplasm
FLJ11710 hypothetical protein FLJ11710 A_23_P3921 AK021772 21.798 unknown
GABBR1 gamma-aminobutyric acid (GABA) B
receptor, 1
A_23_P93302 NM_001470 21.471 Plasma Membrane
IGHM immunoglobulin heavy constant mu A_24_P417352 BX161420 22.451 Plasma Membrane
unknown Unknown A_23_P91743 unknown 21.884 unknown
unknown Unknown A_24_P481375 AK021668 21.706 unknown
Alpha defensins activation pathway. Solid lines (direct relationship); Dashed lines (indirect relationship).
doi:10.1371/journal.pone.0037708.t005
Figure 4. Overlaid networks and associated pathway analysis. Solid lines (direct relationship); Dashed lines (indirect relationship); Red filled
(up-regulation); and Green filled (down-regulation).
doi:10.1371/journal.pone.0037708.g004
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motif) ligand 18 (CCL-18) [24], or surfactant protein A [25]. Rosas
et al used a multi-analyte approach to screen a panel of 49 serum
proteins and identified a combinatorial signature of 5 proteins that
distinguished IPF patients from controls. MMP7 and MMP1 were
the main components of this signature [15]. In their study, higher
levels of MMP7 appeared to be associated with more severe
disease. Most recently, Richards et al identified 140 patients with
IPF and then validated in another 101 patients increased serum
protein levels of MMP-7, ICAM-1, IL-8, VCAM-1, and S100A12
to be associated with decreased survival (XX). These studiesand
ours demonstrate the emerging trend to identify relevant novel
diagnostic and prognostic biomarkers for IPF in blood. There are
no studies that evaluate on a genome-wide basis the peripheral
blood transcriptome of IPF which relate to diagnostic or
prognostic signatures.
Four of the 13 genes up-regulated in the current study have
functions pertaining to host defense. This raises the question of an
association of advanced disease and sub-clinical infection, or host-
microbe interactions. All of these patients were stable when blood
was drawn without overt signs of infection. Viral infection has
been put forth as a possible trigger of acute exacerbations of IPF
[12]. Two of the 13 genes are a-defensins which are small,
cationic, cysteine-rich antimicrobial peptides that have important
roles in host defense against bacteria, fungi and enveloped viruses
[26]. In humans, a-defensins 1–4 are primarily found in
neutrophils, and b-defensins are found in the epithelia of mucosal
surfaces. Both are up-regulated by bacterial and viral infection
[27,28]. a-defensins are synthesized as inactive precursors
consisting of 29–42 amino acid residues and are activated by
proteolytic cleavage both by MMP7 [29,30]. a-defensin levels in
bronchoalveolar lavage and/or plasma are increased in fibrotic
lung diseases, and significant amounts of a-defensins can be found
outside neutrophils in fibroblastic foci in the lungs of patients with
IPF [31]. Increased a-defensins levels are detected in the lung and
blood of patients with acute exacerbations of IPF [32]. Elevated
serum MMP-7 protein distinguish IPF from other types of diffuse
parenchymal lung disease, and higher serum levels of MMP-7 in
patients with IPF is associated with worse lung function [33].
MMP-7 expression is also up-regulated in lungs of patients with
IPF [34]. In inflammatory lung disease complicated by fibropro-
liferation, it has been reported that a-defensins may contribute to
the fibrotic response [12,35,36]. These data support the hypothesis
that elevated levels of a-defensins may be an important substrate
for MMP-7, and this interaction may be related to worsening
physiologic function (DLCO).
Differential-expression analysis demonstrates up-regulation of
the cathelicidin antimicrobial peptide (CAMP) between the severe
IPF subgroup compared to controls, and between mild and severe
disease groups. Cathelicidin is an antimicrobial protein of the
innate immune system stored in peroxidase-negative granules of
neutrophils [37]. CAMP is widely distributed, expressed in lung
tissue, and detected in peripheral blood, plasma as well as
bronchoalveolar lavage fluid (BAL) [38]. CAMP is another
molecule of innate immunity that distinguishes mild from severe
disease. While hypothetical protein FLJ11710 was down regulated
in IPF groups compared to controls, little is known about its
molecular functionality. CEACAM proteins have previously been
shown to bind gram negative bacteria and are also over-expressed
in lung cancers, associated with anti-apoptotic properties and
tumor metastases. The CEACAM-1 gene encodes for glycosylat-
ed, glycosylphosphatidylinositol (GPI) anchored proteins that are
expressed in alveolar epithelial cells [39]. Olfactomedin 4 is
expressed primarily in bone marrow cells, but also in prostate,
small intestine, colon, and stomach, and is upregulated in cancers
of the stomach, colon, breast, and lung [40,41]. Olfactomedin 4
appears to promote S-phase transition, and is a marker of
intestinal stem cells [42]. An explanation for the increased
expression of olfactomedin 4 in the peripheral blood of IPF
patients, and its ability to distinguish mild from severe disease, is
difficult.
There are limitations to this study. Given the minimal disease
burden and lack of clinical symptoms, five cases of mild IPF were
not appropriate candidates for surgical lung biopsy, and therefore
did not have surgical tissue. Due to the minimal disease burden,
they did not meet HRCT criteria of definite IPF according to the
2011 ATS/ERS/JRS/ALAT consensus statement. However, in
the five cases the mean age was 70, and 4 cases were male
supporting the diagnosis of IPF. Furthermore, these cases cluster
with definite mild cases along the principal components (figure 1).
Figure 5. Alpha defensins activation pathway. Solid lines (direct relationship); Dashed lines (indirect relationship).
doi:10.1371/journal.pone.0037708.g005
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current criteria, they very likely represent an early stage of IPF
when all the definite criteria of disease cannot be met.
Furthermore, the fact that these cases cluster with definite cases
based on the peripheral blood signature demonstrates the
feasibility of the peripheral blood gene expression signature as a
diagnostic tool for early stage disease when HRCT findings are
often ambiguous. There is no longitudinal data on the early cases
to determine disease progression or other clinical variables. We
have identified a signature that distinguishes disease extent (%
predicted DLCO), but not when correlated with by FVC %
predicted. The reason for this difference is unclear. FVC is
traditionally used to stage the severity of pulmonary fibrosis.
However, it has been recognized that a single measurement of the
FVC is not useful for predicting disease progression or mortality of
IPF [43]. In contrast, a 10 % decrease in FVC is associated with
increased mortality in IPF [43]. Had we been able to obtain serial
measurements of FVC, then perhaps we might have found an
association with peripheral blood gene expression, disease severity,
and FVC. In contrast, a single measurement of DLCO ,50%
predicts an increased mortality [43]. Therefore, it is possible that
the peripheral blood signatures described correlate with disease
progression as measured by a single DLCO% predicted but not a
single FVC% predicted measurement due to the better perfor-
mance of a single measurement of DLCO compared to FVC. A
lack of correlation between FVC and severity of IPF can be due to
concomitant emphysema, however review of the subject’s HRCT
in this study does not demonstrate significant amounts of
emphysema. It is possible the signature is a consequence of
impaired oxygen transport, but this seems unlikely since two of the
thirteen genes also distinguish controls from mild disease where
oxygen transport is not a factor. Also, none of the 13 genes have
functions related to oxygen transport, aerobic or anaerobic
metabolism, or other pathways that might be implicated in the
presence of hypoxemia or impaired oxygenation.
In summary, our results demonstrate that the peripheral blood
transcriptome can potentially distinguish extent of disease in
individuals with IPF when samples are correlated with percent
predicted DLCO, and distinguish IPF patients from normal. Our
data is consistent with a role for MMP-7 interacting with a-
defensins, and increased expression of host defense proteins in the
peripheral blood being associated with deterioration of DLCO in
IPF. The ability to use a peripheral blood biomarker to monitor
disease progression for IPF could have a substantial impact on the
diagnosis, treatment, and management of this disease, and perhaps
be generally applicable to other subtypes of idiopathic interstitial
pneumonias.
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